Last update 23 Nov 2025
Rui Therapeutics Co., Ltd

Rui Therapeutics Co., Ltd

Private Company|2021|Guangdong Sheng, China

Overview

Basic Info

Introduction
Enrikenuo is a biotech firm specializing in the development of innovative cell therapies utilizing CAR-NK technology.

Tags

Immune System Diseases
Other Diseases
Skin and Musculoskeletal Diseases
CAR-NK
CAR-T
Natural Killer Cell Therapies

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases3
Immune System Diseases3
Nervous System Diseases2
Neoplasms2
Infectious Diseases1
Top 5 Drug TypeCount
CAR-NK8
CAR-T2
Natural Killer Cell Therapies1
Top 5 TargetCount
BCMA x CD192
CD19(B-lymphocyte antigen CD19)1

Related

11
Drugs associated with Rui Therapeutics Co., Ltd
RN-1201
Target
BCMA x CD19
Mechanism
BCMA modulators [+1]
Active Org.
AlloRunning Therapeutics Co., Ltd. [+1]
Originator Org.
AlloRunning Therapeutics Co., Ltd.
Active Indication
Autoimmune Haemolytic Anaemias [+6]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
KN-5501
Target
CD19
Mechanism
CD19 inhibitors [+2]
Active Org.
Rui Therapeutics Co., LtdRui Therapeutics Co., Ltd
Originator Org.
Rui Therapeutics Co., LtdRui Therapeutics Co., Ltd
Active Indication
Idiopathic Inflammatory Myopathies [+7]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Autologous NK Cells(Rui Therapeutics)
Target-
Mechanism-
Active Org.
Rui Therapeutics Co., LtdRui Therapeutics Co., Ltd
Originator Org.
Rui Therapeutics Co., LtdRui Therapeutics Co., Ltd
Active Indication
Multiple Pulmonary Nodules [+2]
Inactive Indication-
Drug Highest PhaseEarly Phase 1
First Approval Ctry. / Loc.-
First Approval Date-
10
Clinical Trials associated with Rui Therapeutics Co., Ltd
NCT07241468
/ Not yet recruitingEarly Phase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
NCT07185035
/ RecruitingEarly Phase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
NCT07105735
/ Not yet recruitingPhase 1IIT
An Exploratory Clinical Study on Allogeneic CAR-T Cell (RN1201) Injection for Autoimmune Diseases Refractory to Standard Therapies
100 Clinical Results associated with Rui Therapeutics Co., Ltd
Login to view more data
0 Patents (Medical) associated with Rui Therapeutics Co., Ltd
Login to view more data
100 Deals associated with Rui Therapeutics Co., Ltd
Login to view more data
100 Translational Medicine associated with Rui Therapeutics Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
4
Phase 1
Other
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
KN-5501
 ( CD19 )		Scleroderma, Systemic
More
Phase 1
RN-1201
 ( BCMA x CD19 )		Autoimmune Haemolytic Anaemias
More
Phase 1
Autologous NK Cells(Rui Therapeutics)
Solitary Pulmonary Nodule
More
Early Phase 1
RN1101
 ( BCMA x CD19 )		Multiple Myeloma
More
Early Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free